Difference between revisions of "Sacituzumab govitecan (Trodelvy)"
Jump to navigation
Jump to search
m (Jwarner moved page Sacituzumab govitecan (IMMU-132) to Sacituzumab govitecan (Trodelvy): FDA approval) |
m |
||
Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=736415 NCI Drug Dictionary]: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=736415 NCI Drug Dictionary]: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. | ||
− | == | + | ==Diseases for which it is used== |
− | + | *[[Breast_cancer,_triple_negative|TNBC]] | |
− | |||
− | |||
− | |||
− | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
Line 25: | Line 21: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
− | |||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] |
Revision as of 00:02, 25 April 2020
Mechanism of action
From the NCI Drug Dictionary: An antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis.
Diseases for which it is used
History of changes in FDA indication
- 4/22/2020: Granted accelerated approval for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.
Also known as
- Code names: IMMU-132, RS7-SN38
- Generic name: sacituzumab govitecan-hziy
- Brand name: Trodelvy